Intellia's Stock Surge: FDA Green Light Ignites Valuation Debate for Gene Editing Pioneer
The FDA's decision to lift a clinical hold on Intellia Therapeutics' pivotal Phase 3 trial has sent its shares soaring, reigniting a fierce debate among investors over whether the gene-editing biotech's potential is already priced in or if significant upside remains.